If you are wondering whether Geron’s current share price reflects its true worth, you are not alone. The stock’s recent moves have put valuation firmly in the spotlight. Over the last 7 days the share ...

For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic ...

Geron unveiled its first-quarter numbers well before market open, showing that the oncology-focused biotech earned $39.6 million during the period. Nearly all of this was derived from sales of Rytelo, ...

In early March 2026, Geron Corporation filed a universal shelf registration covering common stock, preferred stock, debt securities and warrants, and registered an at-the-market follow-on equity ...

Geron Corporation (NASDAQ:GERN) is one of the 13 Best American Penny Stocks to Invest In. On January 29, TD Cowen analyst ...

Geron (GERN) stock drops premarket as the company's Q4 revenue misses estimates despite a sequential rise in Rytelo sales.

The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635 (c) (4) and are subject to the terms and conditions of Geron’s ...

The company now has a reliable revenue stream thanks to its first commercialized drug. Nevertheless, analysts were expecting higher revenue in its first quarter. Geron unveiled its first-quarter ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to ...